Serum Profiling to Distinguish Early- and Late-Stage Ovarian Cancer Patients from Disease-Free Individuals

James R. HockerDepartments of Biochemistry and Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA,

Erin A. BishopDepartments of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA,

Stan A. LightfootDepartments of Pathology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA,

Megan R. LernerDepartments of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA

Marvin D. PeytonDepartments of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA

Daniel J. BrackettDepartments of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA

Rushie J. HanasDepartments of Biochemistry and Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA,

D. Scott McMeekinDepartments of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA,

Joan L. WalkerDepartments of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA,

Jay S. HanasCorrespondence[email protected]

show all

Abstract

Sera mass spectrometry (MS) peak differences were analyzed from 35 ovarian cancer patients and 16 disease-free individuals. “Leave one out” cross validation was used to assign “% cancer peaks” in control and ovarian cancer sera samples. Sera MS discriminated stage I/II and stage III/V ovarian cancer patients versus controls with ROC curve area values of 0.82 and 0.92. Test sensitivities for ovarian cancer stage I/II and III/V were 80% and 93% respectively. These results indicate that MS is useful for distinguishing sera from early-stage ovarian cancer patients, and has potential as a test for early detection of this disease.

Keywords: :

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Serum Profiling to Distinguish Early- and Late-Stage Ovarian Cancer Patients from Disease-Free Individuals

Information for

Open access

Opportunities

Help and information

Serum Profiling to Distinguish Early- and Late-Stage Ovarian Cancer Patients from Disease-Free Individuals

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature